SEC 13F Intelligence

Boxer Capital, LLC / CGEM

Boxer Capital, LLC’s Cullinan Therapeutics Inc Position

Does Boxer Capital, LLC own Cullinan Therapeutics Inc (CGEM)? Not currently — the last reported position was 907.9K shares worth $15M in Q3 2024; the fund’s latest 13F (Q4 2024) no longer reports it.

Position Value
$15M
Q3 2024
Shares
907.9K
% of Portfolio
+0.75%
Quarters Held
13
position exited

Position History CGEM

Reported value by quarter
Q1 ’21: $45MQ1 ’21Q2 ’21: $28MQ3 ’21: $24MQ3 ’21Q4 ’21: $17MQ1 ’22: $11MQ1 ’22Q2 ’22: $14MQ3 ’22: $14MQ3 ’22Q4 ’22: $11MQ1 ’23: $10,988Q1 ’23Q2 ’23: $11,557Q3 ’23: $10MQ3 ’23Q2 ’24: $11MQ3 ’24: $15MQ3 ’24filingsflow.com
QuarterSharesValue% of Portfolio
Q3 2024907.9K$15M+0.75%
Q2 2024657.9K$11M+0.60%
Q3 20231.07M$10M+0.52%
Q2 20231.07M$11,557+0.54%
Q1 20231.07M$10,988+0.54%
Q4 20221.07M$11M+0.60%
Q3 20221.07M$14M+0.77%
Q2 20221.07M$14M+0.87%
Q1 20221.07M$11M+0.58%
Q4 20211.07M$17M+0.64%
Q3 20211.07M$24M+0.85%
Q2 20211.07M$28M+0.98%
Q1 20211.07M$45M+1.52%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Boxer Capital, LLC’s full portfolio or all institutional holders of CGEM.